Search clinical trials for: BBI-001

Total 5277 results

DermBiont, Inc.

Suspended

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis

Onychomycosis

United States
DermBiont, Inc.

Active, not recruiting

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis

Tinea Pedis

United States
University of Pennsylvania

Terminated

Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection

Recurrent Clostridium Difficile Infection

United States
Revibe Technologies

Completed

Assessing a Wearable Digital Therapy for Youth With ADHD

ADHD

United States
University of Pennsylvania

Terminated

Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)

Severe Clostridium Difficile Infection | Severe-Complicated/Fulminant Clostridium Difficile Infection

United States
University of Manitoba
Canadian Institutes of Health Research (CIHR); Canadian Cancer Society (CCS); The Canadian Collaborative for Childhood Cannabinoid Therapeutics

Not yet recruiting

CANnabinoids in Pediatric ONCology (CAN-PONC)

Cancer | Childhood Cancer
Apollomics Inc.

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

Gastric Cancer | Pancreatic Cancer | NSCLC | Lung Cancer | Brain Tumor | Glioblastoma Multiforme | Advanced Cancer | Colon Cancer | Solid Tumors | Thyroid Cancer | Renal Cancer | Gastroesophageal Junction Adenocarcinoma | EGFR Gene Mutation | MET Amplification | HGF | MET Alteration | MET Fusion | Exon 14 Skipping

United States, Spain, France, United Kingdom, Taiwan, Australia, Finland, Italy, Singapore, Hungary, Canada, Puerto Rico, Russian Federation
EyeGene Inc.
Novotech (Australia) Pty Limited

Completed

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers

Prevention of Herpes Zoster (HZ)

Australia
Patagonia Pharmaceuticals, LLC

Completed

A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis

Congenital Ichthyosis

United States
DermBiont, Inc.
Derm Research, PLLC; Northsoundderm; ClearDermatologyandAestheticsCenter

Terminated

Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel

Atopic Dermatitis

United States
Building Block Nutritionals, LLC
Paidion Research, Inc.

Completed

Growth and Safety Study of an Infant Formula for Healthy Term Infants

Infant Development

United States
Celgene

Withdrawn

A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies

Solid Tumor

United States
Hvivo
Prep Biopharm Limited

Completed

Study Examining PrEP-001 in Subjects With Asthma

Asthma
Eleven Biotherapeutics

Completed

Phase 1 Study for Safety and Tolerability of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects (EBI-005-1)

Dry Eye

United States
PMG Pharm Co., Ltd

Completed

Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate Drugs

Arthritis

Korea, Republic of
Kukje Pharma

Completed

[KSR-001-P01]Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristic of KSR-001

Dry Eye Syndromes

Korea, Republic of
EGEN, Inc.

Terminated

Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer

Ovarian Neoplasms

United States
Celgene
Celgene Corporation

Terminated

A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas

Advanced Solid Tumors

United States
Sentien Biotechnologies, Inc.

Active, not recruiting

A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy

COVID-19 | Sepsis | Acute Kidney Injury

United States
Eleven Biotherapeutics

Withdrawn

Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema

Diabetic Macular Edema
Bond Biosciences

Terminated

A Study to Evaluate BBI-001 in Hereditary Haemochromatosis (HH) Patients and Iron Deficient Volunteers

Hereditary Hemochromatosis

Australia
Bridge Biotherapeutics, Inc.
KCRN Research, LLC

Completed

First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers

Ulcerative Colitis

United States
Eleven Biotherapeutics

Completed

A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis (EBI-005-AC-2)

Allergic Conjunctivitis (AC)

United States
Sentien Biotechnologies, Inc.

Active, not recruiting

A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy

Acute Kidney Injury

United States
Hvivo
Prep Biopharm Limited

Completed

Study Examining PrEP-001 in Healthy Subjects

Influenza A H3N2

United Kingdom
Pfizer

Completed

A Study to Assess the Safety and Tolerability of Different Doses of PF-05402536 and PF-06413367 in Healthy Adult Smokers.

Smoking | Vaccines

Canada
National Cancer Institute (NCI)

Completed

Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

Head and Neck Cancer | Head and Neck Neoplasms

United States
Hillhurst Biopharmaceuticals, Inc.
National Heart, Lung, and Blood Institute (NHLBI)

Not yet recruiting

A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)

Anemia, Sickle Cell

United States
EGEN, Inc.

Completed

Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer

Ovarian Neoplasms

United States
101 Therapeutics

Active, not recruiting

Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects

Virus Diseases | COVID-19 | Infectious Disease | Glucocorticoids Toxicity

India
California State University, Long Beach

Completed

Active Moms Project: Physical Activity Intervention for Low-Income Mothers

Physical Inactivity
Botanix Pharmaceuticals

Completed

A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis

Hyperhidrosis

United States
Alaunos Therapeutics

Completed

Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma

Melanoma

United States
Dr. August Wolff GmbH & Co. KG Arzneimittel
Parexel

Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of WOL071-007 in Atopic Dermatitis Patients

Dermatitis, Atopic

Germany
Hillhurst Biopharmaceuticals, Inc.
National Heart, Lung, and Blood Institute (NHLBI)

Completed

A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers

Anemia, Sickle Cell

United States
TR Therapeutics

Completed

Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation

Wounds

United States
NewG Lab Pharma

Active, not recruiting

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Fibrolamellar Carcinoma

Korea, Republic of
Memorial Sloan Kettering Cancer Center
BMS Foundation

Recruiting

Study of Peripheral Arterial Disease (PAD) in People With Cancer Who Will Be Having Surgery

Peripheral Arterial Disease (PAD) in Cancer Patients

United States
Botanix Pharmaceuticals

Completed

A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis

Hyperhidrosis

United States
Antengene Corporation

Terminated

A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (MATCH)

Relapsed/Refractory Diffuse Large B-cell Lymphoma

China
Botanix Pharmaceuticals

Completed

A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis

Hyperhidrosis
Allergan

Completed

A Study of Bimatoprost 0.01% in the Clinical Setting (APPEAL-Taiwan)

Ocular Hypertension | Glaucoma, Primary Open Angle

Taiwan
EyeGene Inc.
Novotech (Australia) Pty Limited

Active, not recruiting

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers

COVID-19 Vaccine

Australia
Cryonove Pharma
CEISO; Dermatech; Sefako Makgatho Health Sciences University

Completed

Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots.

Solar Lentigo | Post-inflammatory Hyperpigmentation | Senile Lentigo

South Africa
IVIEW Therapeutics Inc.

Not yet recruiting

IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Cryonove Pharma
CEISO; Dermatech; LTD HEALTH

Completed

Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots

Lentigo Solar

Georgia
The University of Texas at San Antonio
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... and other collaborators

Completed

Míranos! Program, a Preschool Obesity Prevention RCT

Obesity | Physical Activity | Health Knowledge, Attitudes, Practice | Healthy Eating | Gross Motor Development

United States
Istituti Clinici Scientifici Maugeri SpA
Azienda Ospedaliera Città della Salute e della Scienza di Torino

Completed

Italian Validation of the Beaumont Behavioural Inventory (BBI) (BBI)

Amyotrophic Lateral Sclerosis

Italy
Medtronic Endovascular

Terminated

FlowMet-R Blood Flow Measurement for the Diagnosis of Peripheral Artery Disease and Critical Limb Ischemia

Peripheral Artery Disease

United States
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors

Cancer | Advanced Solid Tumors

United States

Search clinical trials for: BBI-001

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations